TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Adipocytokines in Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women diagnosed with endometrial cancer~2. Age 18 or above~3. Of sound mind so they can give informed consent~4. Historical tissue sample/ blocks from previous cases in the laboratory in the University of Surrey, also be used if appropriate consent is in place.~Exclusion Criteria:~1. Under 18yrs age~2. Unable to give consent /denies consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with endometrial cancer (Type: EXPERIMENTAL): Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.~Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.~Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.~For the women undergoing chemotherapy, blood sample will be procured prior to commencing chemotherapy and after 3rd (with the blood test before the fourth cycle of chemotherapy) and 6th cycles of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Comatose with Blantyre Comas Score ≤ 3~* P. falciparum parasitemia~* Active seizure~Exclusion Criteria:~* Serum creatinine \> 2mg/dL~* Pre-admission/concomitant treatment with antiretroviral medications for HIV (ARVs), antituberculous treatments(ATTs), or chronic use of any other enzyme-inducing medications

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- LEVETIRACETAM (Type: OTHER): Open label, dose escalation to optimal dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methadone vs Magnesium in Spinal Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 12, and younger than 19 years of age undergoing posterior spinal fusion for idiopathic scoliosis~* American Society of Anesthesiologist (ASA) physical status I or II~* Parents/Guardian willing and able to authorize informed consent~* Patients willing and able to authorize assent~Exclusion Criteria:~* Patients presenting with neuromuscular scoliosis~* Patients deemed at increased risk of adverse reactions due to the presence of pre-existing severe organ system dysfunction, including debilitating lung disease, severe obstructive sleep apnea, severe congenital or acquired heart disease, and/or severe renal impairment~* Patients who are both being currently treated for a psychological disorder and have a history of hospitalization for said disorder

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): This arm will receive remifentanil alone as is the current practice.
- Remifentanil plus methadone (Type: EXPERIMENTAL): This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
- Remifentanil plus magnesium (Type: EXPERIMENTAL): This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be medically stable on the basis of clinical laboratory tests~* Diagnostic for major depressive disorder (MDD) without psychotic features~* Have an inadequate response to at least 1 antidepressant in the current episode of depression and at least one other inadequate treatment response to an antidepressant either in the current episode or in a previous episode~* Women must be not pregnant; women must be postmenopausal, surgically sterile or, if heterosexually active, practicing a highly effective method of birth control during the study and for 3 months after receiving the last dose of study drug~* Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug~* Signed informed consent document~Exclusion Criteria:~* History of, or current signs and symptoms of diseases or conditions that would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments~* Has uncontrolled hypertension (systolic blood pressure (SBP)\> 160 mmHg or diastolic blood pressure (DBP)\> 90 mmHg despite diet, exercise or a stable dose of an allowed anti-hypertensive treatment) or any past history of hypertensive crisis~* Has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection, or have positive results at screening~* Has a primary diagnosis of current (active) generalized anxiety disorder, panic disorder, obsessive compulsive disorder, posttraumatic stress disorder, anorexia nervosa, or bulimia nervosa~* Has a history or current diagnosis of a psychotic disorder, bipolar disorder, mental retardation, or borderline personality disorders, mood disorder with postpartum onset, somatoform disorders or chronic fatigue syndrome~* Has had major surgery, (eg, requiring general or local anesthesia) within 4 weeks before screening, or will not have fully recovered from surgery, or planned surgery during the time the subject is expected to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Esketamine (Group 1) (Type: EXPERIMENTAL): None
- Esketamine (Group 2) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be healthy based on medical history, laboratory work, and physical exam~* Be ≥18 and ≤65 years of age~* Females of childbearing potential must not be pregnant and be using an acceptable form of birth control~* Must be free of any systemic or dermatologic disorder~Key Exclusion Criteria:~* Use of prescription medication within 14 days or over-the-counter products within 7 days prior to study medication~* Current use of opioids~* Known hypersensitivity or allergy to any of the components of the product formulations~* Any serious illness in the 4 weeks preceding the beginning of treatment that resulted in missed work or hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Lidocaine Patch (Sequence AB) (Type: EXPERIMENTAL): Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
- Lidocaine Patch (Sequence BA) (Type: EXPERIMENTAL): Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:~  * Ductal carcinoma in situ~ * Stage I-III invasive breast cancer~* At least 3 months since completion of all intended local and systemic therapy, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy, and/or endocrine therapy~  * May have declined recommended treatment provided all treatment intended/agreed upon by the patient and treating physician was completed ≥ 3 months ago~* At least 1 healthy intact breast~  * No prior radiotherapy or mastectomy~ * Prior biopsies allowed~* Any hormone-receptor status~PATIENT CHARACTERISTICS:~* Female~* Pre- or post-menopausal~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective nonhormonal contraception~* No active liver disease~* AST and ALT ≤ 3 times upper limit of normal~* Creatinine clearance ≥ 30 mL/min~* No prior hypersensitivity to any 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor or any of its components~* No other concurrent infectious, inflammatory, or autoimmune diseases (at the discretion of principal investigator)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No daily alcohol use \> 3 standard drinks per day~  * Standard drink defined as 10 grams of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor~* No selective estrogen receptor modulator or aromatase inhibitor within the past 3 months~* No hormone replacement therapy (HRT) within the past 3 months~* No prior estrogen and/or progesterone HRT ≥ 5 years in duration~  * Vaginal estrogen preparations allowed~* No concurrent HRT~* No other cholesterol-lowering drug, including a statin, within the past 3 months~* No concurrent itraconazole, ketoconazole, nefazodone, cyclosporine, HIV protease inhibitors, clarithromycin, erythromycin, mibefradil, carbamazepine, bosentan, chaparral, amiodarone, or verapamil~* No concurrent daily grapefruit juice consumption \> 8 ounces per day~* No other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): Simvastatin 40 mg for 24-28 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metoprolol on Thalassemia Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* documented LVEF \< 50% by echocardiography~* B thalassemia~* No decompensated heart failure for at least 4 weeks (hospitalization for CHF, worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)~* have no evidence of acute myocarditis and~* hemoglobin level above 7 gr⁄dL.~Exclusion Criteria:~* pulse rate below 60/min~* systolic blood pressure less than 90 mmHg~* evidence of peripheral vascular disease~* major depression, history of asthma, PR interval more than 240 msec, second or third degree AV block~* major medical diseases including diabetes mellitus requiring insulin injection, hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for human immunodeficiency virus, and other hemoglobinopathies

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- metoprolol (Type: ACTIVE_COMPARATOR): patient or intervention group
- placebo group (Type: ACTIVE_COMPARATOR): control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Subject with CTEPH (WHO Group 4) judged as inoperable due to the localization of the obstruction being surgically inaccessible (i.e., distal disease).~* Female of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception.~Exclusion Criteria:~* Previous pulmonary endarterectomy.~* Recurrent thromboembolism despite sufficient oral anticoagulants.~* Symptomatic acute pulmonary embolism in the 6-month period prior to randomization.~* Known moderate-to-severe restrictive lung disease (i.e., TLC \< 60% of predicted value) or obstructive lung disease (i.e., FEV1 \< 70% of predicted, with FEV1/FVC \< 65%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema).~* Acute or chronic conditions (other than dyspnea) that limit the ability to comply with study requirements in the 3-month period prior to Screening visit or during the Screening period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan 10 mg, oral tablet, to be taken once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo oral tablet, to be taken once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment During Pregnancy in Benin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnancy between 16 and 28 weeks of gestation~* Residence near the maternity clinics~* Intention to continue the ante-natal care and deliver at the study maternity clinic~* Ability to take drugs by oral route~* Written informed consent (parents or guardian if aged \< 18 years)~Exclusion Criteria:~* Pregnancy prior to 16 weeks or after 28 weeks of gestation~* Previous suspected reaction to sulfadoxine-pyrimethamine or mefloquine~* History of neurological or psychiatric event~* Intake of sulfadoxine-pyrimethamine or mefloquine within 4 weeks of enrollment~* Current treatment with halofantrine

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women of non-child bearing potential,~* Between the ages of 18 and 55 inclusive,~* Body mass index from 18 to 33 kg/m2,~* Skin type compatible with the study assessments, and without significant skin allergies, pigmentary disorders, tattoos, or any active dermatologic conditions that might interfere with the study conduct.~Exclusion Criteria:~* Prior or current history of peripheral neuropathy, paraesthesias, dysesthesias, herpes zoster, post-herpetic neuralgia,~* Evidence of any current illness such as a common cold, viral syndrome, or flu-like symptoms, any disturbance of the autonomic nervous system,~* History of Raynaud's phenomenon; Know allergy or intolerance to capsaicin or hot peppers.

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AMG 403 (Type: EXPERIMENTAL): AMG 403 administered as subcutaneous and intravenous doses
- Placebo (Type: PLACEBO_COMPARATOR): No active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants chronically infected with HCV Genotype 4~* HCV RNA viral load of ≥ 10,000 IU/mL~* No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent~* Results of a liver biopsy obtained within three years prior to enrollment to demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are permitted, however, and any prior biopsy is permitted~Exclusion Criteria:~* Evidence of decompensated liver disease~* Documented or suspected Hepatocellular carcinoma (HCC)~* Positive for Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus-1 (HIV-1)/HIV-2 antibody at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-790052 + PegIFNα-2a + Ribavirin (Type: EXPERIMENTAL): * BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~* PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~* Ribavirin 400 mg (2 tablets for participants \< 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response
- Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin (Type: PLACEBO_COMPARATOR): * Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~* PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~* Ribavirin 400 mg (2 tablets for participants \< 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tramadol in Prevention of Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years old ≤ age ≤ 40 years old;~* ASA score I-Ⅱ;~* uncomplicated and singleton full-term pregnancy;~* voluntarily to receive cesarean section and postoperative controlled analgesia;~* consent to participate the study.~Exclusion Criteria:~* with history of mental disorders or psychotropic substances use;~* with history of neurological diseases such as epilepsy~* with history of previously known diagnosed depression;~* with suicidal ideation or history of suicide;~* with history of drug，alcohol or opioid abuse;~* with monoamine oxidase (MAO) inhibitor treatment at present or in the past 14 days;~* participating in other clinical studies~* with severe heart disease, brain disease, liver disease and kidney disease;~* be allergic to tramadol or opioids;~* with any contraindication for combined spinal epidural anesthesia;~* incapable of communication or cooperation.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Group T (Type: ACTIVE_COMPARATOR): All patients receive the patient-controlled intravenous analgesia with Tramadol.
- Group H (Type: PLACEBO_COMPARATOR): All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
- Group E (Type: PLACEBO_COMPARATOR): All patients receive the patient-controlled epidural analgesia with Ropivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete